On Monday, AbCellera Biologics Inc (NASDAQ: ABCL) opened lower -3.48% from the last session, before settling in for the closing price of $3.74. Price fluctuations for ABCL have ranged from $1.89 to $4.09 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -107.74% over the past five years. Company’s average yearly earnings per share was noted -10.77% at the time writing. With a float of $223.95 million, this company’s outstanding shares have now reached $298.36 million.
Let’s look at the performance matrix of the company that is accounted for 596 employees. In terms of profitability, gross margin is -474.21%, operating margin of -1579.18%, and the pretax margin is -911.24%.
AbCellera Biologics Inc (ABCL) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of AbCellera Biologics Inc is 24.97%, while institutional ownership is 41.08%.
AbCellera Biologics Inc (ABCL) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -10.77% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.83% during the next five years compared to -107.74% drop over the previous five years of trading.
AbCellera Biologics Inc (NASDAQ: ABCL) Trading Performance Indicators
Check out the current performance indicators for AbCellera Biologics Inc (ABCL). In the past quarter, the stock posted a quick ratio of 10.15. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 46.61.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.57, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.55 in one year’s time.
Technical Analysis of AbCellera Biologics Inc (ABCL)
AbCellera Biologics Inc (NASDAQ: ABCL) saw its 5-day average volume 6.88 million, a positive change from its year-to-date volume of 4.68 million. As of the previous 9 days, the stock’s Stochastic %D was 65.70%.
During the past 100 days, AbCellera Biologics Inc’s (ABCL) raw stochastic average was set at 78.36%, which indicates a significant increase from 70.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 97.41% in the past 14 days, which was higher than the 77.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.54, while its 200-day Moving Average is $2.70. Nevertheless, the first resistance level for the watch stands at $3.76 in the near term. At $3.91, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.03. If the price goes on to break the first support level at $3.49, it is likely to go to the next support level at $3.37. The third support level lies at $3.22 if the price breaches the second support level.
AbCellera Biologics Inc (NASDAQ: ABCL) Key Stats
There are currently 298,424K shares outstanding in the company with a market cap of 1.08 billion. Presently, the company’s annual sales total 28,830 K according to its annual income of -162,860 K. Last quarter, the company’s sales amounted to 4,240 K and its income totaled -45,620 K.
